Search Results - "Bria, E."

To explain the unexplainable in MONARCH 3 overall survival: the restricted mean survival time. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3' by M. P. Goetz et al by Orlandi, A, Mastrantoni, L, Bria, E, Tortora, G

Get more information

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference by Roila, F., Herrstedt, J., Aapro, M., Gralla, R. J., Einhorn, L. H., Ballatori, E., Bria, E., Clark-Snow, R. A., Espersen, B. T., Feyer, P., Grunberg, S. M., Hesketh, P. J., Jordan, K., Kris, M. G., Maranzano, E., Molassiotis, A., Morrow, G., Olver, I., Rapoport, B. L., Rittenberg, C., Saito, M., Tonato, M., Warr, D.

Get full text

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab by Loibl, S., Majewski, I., Guarneri, V., Nekljudova, V., Holmes, E., Bria, E., Denkert, C., Schem, C., Sotiriou, C., Loi, S., Untch, M., Conte, P., Bernards, R., Piccart, M., von Minckwitz, G., Baselga, J.

“…The predictive value of PIK3CA mutations in HER2 positive (HER2+) breast cancer treated with neoadjuvant anti-HER2 and chemotherapy has been reported, but the…”
Get full text

Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis by Ciccarese, C., Iacovelli, R., Porta, C., Procopio, G., Bria, E., Astore, S., Cannella, M.A., Tortora, G.

“…•VEGFR-TKIs + PD-1 ICIs combinations are a new first-line standard of care in mRCC.•The benefit of VEGFR-TKIs + ICIs is unclear in IMDC favorable mRCC…”
Get full text

Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis by Bria, E., Milella, M., Cuppone, F., Novello, S., Ceribelli, A., Vaccaro, V., Sperduti, I., Gelibter, A., Scagliotti, G.V., Cognetti, F., Giannarelli, D.

“…Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are effective as first-line treatment of advanced non-small-cell lung cancer patients…”
Get full text

Tracking MET de-addiction in lung cancer: A road towards the oncogenic target by Pilotto, S., Carbognin, L., Karachaliou, N., Ma, P.C., Rosell, R., Tortora, G., Bria, E.

“…•The identification of new effective targets in lung cancer remains a high priority.•No impactful results have been achieved with anti-MET agents in unselected…”
Get full text

Chemotherapy Rechallenge or Reintroduction Compared to Regorafenib or Trifluridine/Tipiracil for Pretreated Metastatic Colorectal Cancer Patients: A Propensity Score Analysis of Treatment Beyond Second Line (Proserpyna Study) by Calegari, M.A., Zurlo, I.V., Dell'Aquila, E., Basso, M., Orlandi, A., Bensi, M., Camarda, F., Anghelone, A., Pozzo, C., Sperduti, I., Salvatore, L., Santini, D., Corsi, D.C., Bria, E., Tortora, G.

“…•Optimal treatment for refractory metastatic colorectal cancer is still questioned.•We directly compared the prognostic performance of CTr/r, REG and…”
Get full text

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab by Loibl, S, Majewski, I, Guarneri, V, Nekljudova, V, Holmes, E, Bria, E, Denkert, C, Schem, C, Sotiriou, C, Loi, S, Untch, M, Conte, P, Bernards, R, Piccart, M, von Minckwitz, G, Baselga, J

Get full text

Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies by Di Noia, V., D’Aveni, A., D’Argento, E., Rossi, S., Ghirardelli, P., Bortolotti, L., Vavassori, V., Bria, E., Ceresoli, G.L.

“…A precision medicine approach has been successfully applied in medical oncology for the treatment of non-small-cell lung cancer (NSCLC) through the…”
Get full text

Adherence to dietary guidelines (DG) and body weight change (BWC) in early-stage breast cancer (EBC): A prospective trial in patients submitted to nutrition evidence-based educational intervention by Carbognin, L., Trestini, I., Sperduti, I., Fiorio, E., Tregnago, D., Pilotto, S., Scambia, G., Tortora, G., Milella, M., Bria, E.

Get full text

A clinical–biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status by Bria, E., De Manzoni, G., Beghelli, S., Tomezzoli, A., Barbi, S., Di Gregorio, C., Scardoni, M., Amato, E., Frizziero, M., Sperduti, I., Corbo, V., Brunelli, M., Bersani, S., Tortora, G., Scarpa, A.

“…To obtain a prognostic stratification model for resected gastric cancer patients. Clinicopathological and molecular data (expression of Cdx2, Apc, β-catenin,…”
Get full text

Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis by Bria, E., Pilotto, S., Simbolo, M., Fassan, M., de Manzoni, G., Carbognin, L., Sperduti, I., Brunelli, M., Cataldo, I., Tomezzoli, A., Mafficini, A., Turri, G., Karachaliou, N., Rosell, R., Tortora, G., Scarpa, A.

“…In this study, we evaluated whether the presence of genetic alterations detected by next generation sequencing may define outcome in a prognostically-selected…”
Get full text

Bevacizumab (BV) maintenance after first-line chemotherapy plus BV for metastatic colorectal cancer patients: a meta-analysis of individual patients data from 3 phase III studies by Salvatore, L., Bria, E., Sperduti, I., Hinke, A., Hegewisch-Becker, S., Aparicio, T., Le Malicot, K., Boige, V., Koeberle, D., Baertschi, D., Dietrich, D., Tortora, G., Arnold, D.

Get full text

Corrections to “PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab” by Loibl, S., Majewski, I., Guarneri, V., Nekljudova, V., Holmes, E., Bria, E., Denkert, C., Schem, C., Sotiriou, C., Loi, S., Untch, M., Conte, P., Bernards, R., Piccart, M., von Minckwitz, G., Baselga, J.

Get full text

Chemotherapy rechallenge or reintroduction, regorafenib, and TAS-102 for metastatic pretreated colorectal cancer patients: a propensity score analysis of treatment beyond the second line (PROSERpINA Study) by Calegari, M., Zurlo, I., Basso, M., Orlandi, A., Bensi, M., Camarda, F., Stefano, B. Di, Vivolo, R., Pozzo, C., Sperduti, I., Bria, E., Salvatore, L., Tortora, G.

Get full text

Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis by Palazzo, A., Ciccarese, C., Iacovelli, R., Cannizzaro, M.C., Stefani, A., Salvatore, L., Bria, E., Tortora, G.

“…Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) provided significant antitumor activity in various tumors, mainly carrying deleterious mutations of…”
Get full text

Monitoring of blood serum amyloid (SAA) to predict outcome of first-line pembrolizumab (P) in patients (pts) with advanced non-small cell lung cancer (ANSCLC) by Di Noia, V., D’Argento, E., Vita, E., Ferrara, M., Damiano, P., Ribelli, M., Cannella, A., Virtuoso, A., Tortora, G., Bria, E.

Get full text

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab by Loibl, S, Majewski, I, Guarneri, V, Nekljudova, V, Holmes, E, Bria, E, Denkert, C, Schem, C, Sotiriou, C, Loi, S, Untch, M, Conte, P, Bernards, R, Piccart, M, von Minckwitz, G, Baselga, J

Get full text

Tubulin inhibitors in non-small cell lung cancer: looking back and forward by Ferrara, R, Pilotto, S, Peretti, U, Caccese, M, Kinspergher, S, Carbognin, L, Karachaliou, N, Rosell, R, Tortora, G, Bria, E

“…Although the advent of target therapy for lung cancer has brought about outstanding results, this benefit is confined to a subgroup of molecularly selected…”
Get more information

Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis by Di Maio, M., Baratelli, C., Bironzo, P., Vignani, F., Bria, E., Sperti, E., Marcato, M., Roila, F.

Get full text